Complete response to the combination therapy with androgen blockade and somatostatin analogue in a patient with advanced prostate cancer: magnetic resonance imaging with 1H-spectroscopy

Eur Urol. 2008 Mar;53(3):652-5. doi: 10.1016/j.eururo.2007.02.010. Epub 2007 Feb 15.

Abstract

A 74-yr-old man with prostatic adenocarcinoma underwent magnetic resonance 1H-spectroscopic imaging (1H-MRSI) of the prostate. Based on the results, he was treated with combination therapy using complete androgen blockade (leuprorelin acetate 3.75 mg every 4 wk plus bicalutamide 50 mg daily) and a somatostatin analogue (lanreotide acetate 60 mg every 4 wk). Serum prostate-specific antigen and chromogranin A levels steadily decreased over a 12-mo follow-up period, at which time the patient is alive without disease progression and with a complete objective and symptomatic response.

Publication types

  • Case Reports

MeSH terms

  • Acromegaly
  • Adenocarcinoma / diagnosis
  • Adenocarcinoma / drug therapy*
  • Aged
  • Androgen Antagonists / administration & dosage
  • Androgen Antagonists / therapeutic use*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use
  • Diagnosis, Differential
  • Drug Therapy, Combination
  • Follow-Up Studies
  • Humans
  • Leuprolide / administration & dosage
  • Leuprolide / therapeutic use*
  • Magnetic Resonance Spectroscopy / methods*
  • Male
  • Peptides, Cyclic / administration & dosage
  • Peptides, Cyclic / therapeutic use*
  • Prostatic Neoplasms / diagnosis
  • Prostatic Neoplasms / drug therapy*
  • Severity of Illness Index
  • Somatostatin / administration & dosage
  • Somatostatin / analogs & derivatives*
  • Somatostatin / therapeutic use
  • Time Factors

Substances

  • Androgen Antagonists
  • Antineoplastic Agents
  • Peptides, Cyclic
  • lanreotide
  • Somatostatin
  • Leuprolide